CA2926724A1 - Genetic markers predictive of response to glatiramer acetate - Google Patents
Genetic markers predictive of response to glatiramer acetate Download PDFInfo
- Publication number
- CA2926724A1 CA2926724A1 CA2926724A CA2926724A CA2926724A1 CA 2926724 A1 CA2926724 A1 CA 2926724A1 CA 2926724 A CA2926724 A CA 2926724A CA 2926724 A CA2926724 A CA 2926724A CA 2926724 A1 CA2926724 A1 CA 2926724A1
- Authority
- CA
- Canada
- Prior art keywords
- location
- genotype
- snps
- snp
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims abstract description 174
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims abstract description 172
- 229960003776 glatiramer acetate Drugs 0.000 title claims abstract description 172
- 230000004044 response Effects 0.000 title description 100
- 230000002068 genetic effect Effects 0.000 title description 65
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 125
- 238000000034 method Methods 0.000 claims abstract description 97
- 241000282414 Homo sapiens Species 0.000 claims abstract description 79
- 239000002773 nucleotide Substances 0.000 claims abstract description 43
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 43
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 239000003937 drug carrier Substances 0.000 claims abstract description 13
- 108700028369 Alleles Proteins 0.000 claims description 219
- 108090000623 proteins and genes Proteins 0.000 claims description 119
- 238000004458 analytical method Methods 0.000 claims description 117
- 239000000523 sample Substances 0.000 claims description 61
- 238000003752 polymerase chain reaction Methods 0.000 claims description 36
- 238000003205 genotyping method Methods 0.000 claims description 35
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 32
- 239000003153 chemical reaction reagent Substances 0.000 claims description 23
- 102220004786 rs241447 Human genes 0.000 claims description 23
- 102220211762 rs241442 Human genes 0.000 claims description 22
- 102220211807 rs241449 Human genes 0.000 claims description 22
- 238000012163 sequencing technique Methods 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- 238000003776 cleavage reaction Methods 0.000 claims description 17
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 17
- 230000007017 scission Effects 0.000 claims description 17
- 238000003556 assay Methods 0.000 claims description 12
- 206010061818 Disease progression Diseases 0.000 claims description 10
- 230000005750 disease progression Effects 0.000 claims description 10
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000004422 calculation algorithm Methods 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 238000000018 DNA microarray Methods 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 230000000875 corresponding effect Effects 0.000 description 65
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 39
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 39
- 239000000902 placebo Substances 0.000 description 38
- 229940068196 placebo Drugs 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 32
- 239000000654 additive Substances 0.000 description 32
- 230000000996 additive effect Effects 0.000 description 32
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 27
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 27
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 27
- 238000003491 array Methods 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 101001053590 Homo sapiens IQ domain-containing protein K Proteins 0.000 description 21
- 101000723615 Homo sapiens Zinc finger protein 536 Proteins 0.000 description 21
- 102100024415 IQ domain-containing protein K Human genes 0.000 description 21
- 102100027858 Zinc finger protein 536 Human genes 0.000 description 21
- 241001575928 Siler Species 0.000 description 20
- 230000003902 lesion Effects 0.000 description 18
- 101001104100 Homo sapiens Rab effector Noc2 Proteins 0.000 description 17
- 102100040095 Rab effector Noc2 Human genes 0.000 description 17
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 17
- 102100032596 Fibrocystin Human genes 0.000 description 16
- 101000730595 Homo sapiens Fibrocystin Proteins 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 13
- 108091006583 SLC14A2 Proteins 0.000 description 13
- 102100031085 Urea transporter 2 Human genes 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000002974 pharmacogenomic effect Effects 0.000 description 13
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 11
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 11
- 102100035654 Cathepsin S Human genes 0.000 description 11
- 101000657326 Homo sapiens Protein TANC2 Proteins 0.000 description 11
- 102100034784 Protein TANC2 Human genes 0.000 description 11
- 239000013256 coordination polymer Substances 0.000 description 11
- 238000002595 magnetic resonance imaging Methods 0.000 description 11
- 108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 description 10
- 102000002312 GDPmannose 4,6-dehydratase Human genes 0.000 description 10
- 101001050038 Homo sapiens Kalirin Proteins 0.000 description 10
- 101000578932 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 10
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 10
- 101001062760 Homo sapiens Protein FAM13A Proteins 0.000 description 10
- 102100023093 Kalirin Human genes 0.000 description 10
- 102100028328 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Human genes 0.000 description 10
- 102100024304 Protachykinin-1 Human genes 0.000 description 10
- 102100030557 Protein FAM13A Human genes 0.000 description 10
- 239000010437 gem Substances 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 102000017926 CHRM2 Human genes 0.000 description 9
- 101000928929 Homo sapiens Muscarinic acetylcholine receptor M2 Proteins 0.000 description 9
- 101000694802 Homo sapiens Receptor-type tyrosine-protein phosphatase T Proteins 0.000 description 9
- ADLSWZDEMJETGK-UHFFFAOYSA-N I.I.I.I.I.I.I.I.I.I.I Chemical compound I.I.I.I.I.I.I.I.I.I.I ADLSWZDEMJETGK-UHFFFAOYSA-N 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 102100028645 Receptor-type tyrosine-protein phosphatase T Human genes 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000012937 correction Methods 0.000 description 9
- 102100031235 Chromodomain-helicase-DNA-binding protein 1 Human genes 0.000 description 8
- 102100027309 Cyclic AMP-responsive element-binding protein 5 Human genes 0.000 description 8
- 101000777047 Homo sapiens Chromodomain-helicase-DNA-binding protein 1 Proteins 0.000 description 8
- 101000726193 Homo sapiens Cyclic AMP-responsive element-binding protein 5 Proteins 0.000 description 8
- 101001102158 Homo sapiens Phosphatidylserine synthase 1 Proteins 0.000 description 8
- 102100039298 Phosphatidylserine synthase 1 Human genes 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 8
- 102100033805 Alpha-protein kinase 1 Human genes 0.000 description 7
- 102100025332 Cadherin-9 Human genes 0.000 description 7
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 7
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 7
- 101000779568 Homo sapiens Alpha-protein kinase 1 Proteins 0.000 description 7
- 101000935098 Homo sapiens Cadherin-9 Proteins 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 102200057606 rs231775 Human genes 0.000 description 7
- 102100032360 Alstrom syndrome protein 1 Human genes 0.000 description 6
- 102100024074 Dystrobrevin alpha Human genes 0.000 description 6
- 101150097734 EPHB2 gene Proteins 0.000 description 6
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 6
- 101000797795 Homo sapiens Alstrom syndrome protein 1 Proteins 0.000 description 6
- 101001053689 Homo sapiens Dystrobrevin alpha Proteins 0.000 description 6
- 101000942713 Homo sapiens Liprin-alpha-2 Proteins 0.000 description 6
- 101000580722 Homo sapiens RNA-binding protein 26 Proteins 0.000 description 6
- 101000777263 Homo sapiens UV radiation resistance-associated gene protein Proteins 0.000 description 6
- 102100032894 Liprin-alpha-2 Human genes 0.000 description 6
- 102100027477 RNA-binding protein 26 Human genes 0.000 description 6
- 102100031275 UV radiation resistance-associated gene protein Human genes 0.000 description 6
- 102000013387 Vitamin D3 24-Hydroxylase Human genes 0.000 description 6
- 108010026102 Vitamin D3 24-Hydroxylase Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000013264 cohort analysis Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000000611 regression analysis Methods 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 102100037211 Aryl hydrocarbon receptor nuclear translocator-like protein 1 Human genes 0.000 description 5
- 102100024343 Contactin-5 Human genes 0.000 description 5
- 102100036324 Cytochrome P450 26C1 Human genes 0.000 description 5
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 5
- 101000740484 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 5
- 101000909507 Homo sapiens Contactin-5 Proteins 0.000 description 5
- 101000875398 Homo sapiens Cytochrome P450 26C1 Proteins 0.000 description 5
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 5
- 101000741978 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein Proteins 0.000 description 5
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 5
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 5
- 102100038633 Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein Human genes 0.000 description 5
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 5
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 5
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000012098 association analyses Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 102200050474 rs6897932 Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102100040755 CREB-regulated transcription coactivator 3 Human genes 0.000 description 4
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 4
- 101000891906 Homo sapiens CREB-regulated transcription coactivator 3 Proteins 0.000 description 4
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 4
- 101001047811 Homo sapiens Inactive heparanase-2 Proteins 0.000 description 4
- 101001038562 Homo sapiens Nucleolar protein 4 Proteins 0.000 description 4
- 101000858600 Homo sapiens RING finger and SPRY domain-containing protein 1 Proteins 0.000 description 4
- ZJMSXVSGTCVBQK-UHFFFAOYSA-N I.I.I.I.I.I.I Chemical compound I.I.I.I.I.I.I ZJMSXVSGTCVBQK-UHFFFAOYSA-N 0.000 description 4
- 102100024022 Inactive heparanase-2 Human genes 0.000 description 4
- 102100040316 Nucleolar protein 4 Human genes 0.000 description 4
- 102100028855 RING finger and SPRY domain-containing protein 1 Human genes 0.000 description 4
- 108091006725 SLCO1C1 Proteins 0.000 description 4
- 102100027229 Solute carrier organic anion transporter family member 1C1 Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 102100033648 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3 Human genes 0.000 description 3
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 description 3
- 102100031219 Centrosomal protein of 55 kDa Human genes 0.000 description 3
- 101710092479 Centrosomal protein of 55 kDa Proteins 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 101150099632 Dd gene Proteins 0.000 description 3
- 101000733571 Homo sapiens Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3 Proteins 0.000 description 3
- 101000697871 Homo sapiens BAG family molecular chaperone regulator 3 Proteins 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101001003138 Homo sapiens Interleukin-12 receptor subunit beta-2 Proteins 0.000 description 3
- 101000997920 Homo sapiens Janus kinase and microtubule-interacting protein 3 Proteins 0.000 description 3
- 101000971423 Homo sapiens Lysine-rich nucleolar protein 1 Proteins 0.000 description 3
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 3
- 101000995290 Homo sapiens Protein NDRG3 Proteins 0.000 description 3
- 101000629826 Homo sapiens RNA-binding E3 ubiquitin-protein ligase MEX3C Proteins 0.000 description 3
- 101000870945 Homo sapiens Ras guanyl-releasing protein 3 Proteins 0.000 description 3
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 3
- 101001125059 Homo sapiens Sodium/potassium-transporting ATPase subunit beta-1-interacting protein 2 Proteins 0.000 description 3
- 101000625358 Homo sapiens Transcription initiation factor TFIID subunit 2 Proteins 0.000 description 3
- 101000983956 Homo sapiens Voltage-dependent L-type calcium channel subunit beta-2 Proteins 0.000 description 3
- 101000983936 Homo sapiens Voltage-dependent L-type calcium channel subunit beta-3 Proteins 0.000 description 3
- RCZNYTXJVULKCR-UHFFFAOYSA-N I.I.I.I.I.I.I.I Chemical compound I.I.I.I.I.I.I.I RCZNYTXJVULKCR-UHFFFAOYSA-N 0.000 description 3
- GARLKHGYOJAPHX-UHFFFAOYSA-N I.I.I.I.I.I.I.I.I.I Chemical compound I.I.I.I.I.I.I.I.I.I GARLKHGYOJAPHX-UHFFFAOYSA-N 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 description 3
- 102100033426 Janus kinase and microtubule-interacting protein 3 Human genes 0.000 description 3
- 102100021547 Lysine-rich nucleolar protein 1 Human genes 0.000 description 3
- 101001043810 Macaca fascicularis Interleukin-7 receptor subunit alpha Proteins 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 3
- 102100034435 Protein NDRG3 Human genes 0.000 description 3
- 102100026872 RNA-binding E3 ubiquitin-protein ligase MEX3C Human genes 0.000 description 3
- 102100033450 Ras guanyl-releasing protein 3 Human genes 0.000 description 3
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 3
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 3
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 3
- 102100029417 Sodium/potassium-transporting ATPase subunit beta-1-interacting protein 2 Human genes 0.000 description 3
- 102100025041 Transcription initiation factor TFIID subunit 2 Human genes 0.000 description 3
- 102100025807 Voltage-dependent L-type calcium channel subunit beta-2 Human genes 0.000 description 3
- 102100025838 Voltage-dependent L-type calcium channel subunit beta-3 Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 102100040197 Apolipoprotein A-V Human genes 0.000 description 2
- 102100026288 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 3 Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102100027140 Butyrophilin subfamily 1 member A1 Human genes 0.000 description 2
- 102100021924 Coiled-coil domain-containing protein 9B Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 2
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 2
- 108010048896 HLA-D Antigens Proteins 0.000 description 2
- 102000009485 HLA-D Antigens Human genes 0.000 description 2
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 2
- 101001126430 Homo sapiens 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Proteins 0.000 description 2
- 101000889974 Homo sapiens Apolipoprotein A-V Proteins 0.000 description 2
- 101000785919 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 3 Proteins 0.000 description 2
- 101000984929 Homo sapiens Butyrophilin subfamily 1 member A1 Proteins 0.000 description 2
- 101000897575 Homo sapiens Coiled-coil domain-containing protein 9B Proteins 0.000 description 2
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 2
- 101000603239 Homo sapiens Neuroligin-1 Proteins 0.000 description 2
- 101001098564 Homo sapiens Partitioning defective 3 homolog B Proteins 0.000 description 2
- 101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 2
- 101000904783 Homo sapiens Putative tyrosine-protein phosphatase auxilin Proteins 0.000 description 2
- 101000701446 Homo sapiens Stanniocalcin-2 Proteins 0.000 description 2
- 101000759808 Homo sapiens Testis-expressed basic protein 1 Proteins 0.000 description 2
- 101000785558 Homo sapiens Zinc finger and SCAN domain-containing protein 9 Proteins 0.000 description 2
- RWBZEOYINQWMAW-UHFFFAOYSA-N I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I Chemical compound I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I RWBZEOYINQWMAW-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 102100038992 Neuroligin-1 Human genes 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102100037134 Partitioning defective 3 homolog B Human genes 0.000 description 2
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 2
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 2
- 102100023922 Putative tyrosine-protein phosphatase auxilin Human genes 0.000 description 2
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 2
- 101150114242 SAMHD1 gene Proteins 0.000 description 2
- 102100030510 Stanniocalcin-2 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100023292 Testis-expressed basic protein 1 Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100026624 Zinc finger and SCAN domain-containing protein 9 Human genes 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150000874 11 gene Proteins 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 101100288238 Arabidopsis thaliana KRP5 gene Proteins 0.000 description 1
- 102100030287 Arfaptin-1 Human genes 0.000 description 1
- 102100038105 Arpin Human genes 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 244000024671 Brassica kaber Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102100027138 Butyrophilin subfamily 3 member A1 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100040750 CUB and sushi domain-containing protein 1 Human genes 0.000 description 1
- 101100256077 Caenorhabditis elegans aos-1 gene Proteins 0.000 description 1
- 101100492584 Caenorhabditis elegans ast-1 gene Proteins 0.000 description 1
- 101100179406 Caenorhabditis elegans iff-1 gene Proteins 0.000 description 1
- 101100313377 Caenorhabditis elegans stip-1 gene Proteins 0.000 description 1
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 description 1
- 102100035037 Calpastatin Human genes 0.000 description 1
- 102100026793 Carboxypeptidase A6 Human genes 0.000 description 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 description 1
- 102100037327 Chondrolectin Human genes 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102100040499 Contactin-associated protein-like 2 Human genes 0.000 description 1
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 101150083710 DRG3 gene Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 101100313382 Dictyostelium discoideum stip-2 gene Proteins 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 102100024117 Disks large homolog 2 Human genes 0.000 description 1
- 102100034109 DnaJ homolog subfamily C member 13 Human genes 0.000 description 1
- 102100032086 Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase Human genes 0.000 description 1
- 101100507451 Drosophila melanogaster sip3 gene Proteins 0.000 description 1
- 102100032300 Dynein axonemal heavy chain 11 Human genes 0.000 description 1
- 241001658031 Eris Species 0.000 description 1
- 102000013340 FBXL7 Human genes 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 101150049384 Fbxl7 gene Proteins 0.000 description 1
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 description 1
- 102100032789 Formin-like protein 3 Human genes 0.000 description 1
- 102100030279 G-protein coupled receptor 35 Human genes 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 241000976806 Genea <ascomycete fungus> Species 0.000 description 1
- 102100030652 Glutamate receptor 1 Human genes 0.000 description 1
- 102100037474 Glycosyltransferase-like domain-containing protein 1 Human genes 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050009377 Glypican-5 Proteins 0.000 description 1
- 241001245789 Goodea atripinnis Species 0.000 description 1
- 102100033321 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 Human genes 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 108700039143 HMGA2 Proteins 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 101150073387 Hmga2 gene Proteins 0.000 description 1
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- 101000792706 Homo sapiens Arfaptin-1 Proteins 0.000 description 1
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 description 1
- 101000984934 Homo sapiens Butyrophilin subfamily 3 member A1 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000892017 Homo sapiens CUB and sushi domain-containing protein 1 Proteins 0.000 description 1
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 description 1
- 101000910782 Homo sapiens Carboxypeptidase A6 Proteins 0.000 description 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 description 1
- 101000879734 Homo sapiens Chondrolectin Proteins 0.000 description 1
- 101000749877 Homo sapiens Contactin-associated protein-like 2 Proteins 0.000 description 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 1
- 101001053980 Homo sapiens Disks large homolog 2 Proteins 0.000 description 1
- 101000870239 Homo sapiens DnaJ homolog subfamily C member 13 Proteins 0.000 description 1
- 101000776319 Homo sapiens Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase Proteins 0.000 description 1
- 101001016208 Homo sapiens Dynein axonemal heavy chain 11 Proteins 0.000 description 1
- 101000890757 Homo sapiens FH1/FH2 domain-containing protein 3 Proteins 0.000 description 1
- 101000917234 Homo sapiens Fibroblast growth factor 12 Proteins 0.000 description 1
- 101001009545 Homo sapiens G-protein coupled receptor 35 Proteins 0.000 description 1
- 101001010445 Homo sapiens Glutamate receptor 1 Proteins 0.000 description 1
- 101001026170 Homo sapiens Glycosyltransferase-like domain-containing protein 1 Proteins 0.000 description 1
- 101000926795 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 Proteins 0.000 description 1
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 description 1
- 101001044371 Homo sapiens Immunoglobulin superfamily member 1 Proteins 0.000 description 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
- 101000998140 Homo sapiens Interleukin-36 alpha Proteins 0.000 description 1
- 101000945215 Homo sapiens Kelch-like protein 29 Proteins 0.000 description 1
- 101000590482 Homo sapiens Kinetochore protein Nuf2 Proteins 0.000 description 1
- 101000579886 Homo sapiens Leucine-rich repeat-containing protein 38 Proteins 0.000 description 1
- 101000590691 Homo sapiens MAGUK p55 subfamily member 2 Proteins 0.000 description 1
- 101000588145 Homo sapiens Microtubule-associated tumor suppressor 1 Proteins 0.000 description 1
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 description 1
- 101000957106 Homo sapiens Mitotic spindle assembly checkpoint protein MAD1 Proteins 0.000 description 1
- 101000624956 Homo sapiens Nesprin-2 Proteins 0.000 description 1
- 101000634545 Homo sapiens Neuronal PAS domain-containing protein 3 Proteins 0.000 description 1
- 101000655246 Homo sapiens Neutral amino acid transporter A Proteins 0.000 description 1
- 101000601048 Homo sapiens Nidogen-2 Proteins 0.000 description 1
- 101000982215 Homo sapiens Olfactory receptor 9Q1 Proteins 0.000 description 1
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 description 1
- 101000625494 Homo sapiens Phosphatidate cytidylyltransferase, mitochondrial Proteins 0.000 description 1
- 101000944000 Homo sapiens Potassium channel subfamily T member 2 Proteins 0.000 description 1
- 101001039359 Homo sapiens Probable G-protein coupled receptor 158 Proteins 0.000 description 1
- 101000729531 Homo sapiens Probable phospholipid-transporting ATPase IIB Proteins 0.000 description 1
- 101000956094 Homo sapiens Protein Daple Proteins 0.000 description 1
- 101000855004 Homo sapiens Protein Wnt-7a Proteins 0.000 description 1
- 101000735368 Homo sapiens Protocadherin-9 Proteins 0.000 description 1
- 101001094101 Homo sapiens Putative uncharacterized protein SLC66A1L Proteins 0.000 description 1
- 101000606537 Homo sapiens Receptor-type tyrosine-protein phosphatase delta Proteins 0.000 description 1
- 101000756805 Homo sapiens Repulsive guidance molecule B Proteins 0.000 description 1
- 101000688684 Homo sapiens Sideroflexin-5 Proteins 0.000 description 1
- 101000702010 Homo sapiens Spermatogenesis-associated protein 16 Proteins 0.000 description 1
- 101000873990 Homo sapiens Stabilizer of axonemal microtubules 1 Proteins 0.000 description 1
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 1
- 101000598030 Homo sapiens Talin-2 Proteins 0.000 description 1
- 101000795793 Homo sapiens Tetratricopeptide repeat protein 28 Proteins 0.000 description 1
- 101000598715 Homo sapiens Thrombospondin type-1 domain-containing protein 7B Proteins 0.000 description 1
- 101000680132 Homo sapiens Trimeric intracellular cation channel type B Proteins 0.000 description 1
- 101000659236 Homo sapiens Tubulin polyglutamylase TTLL11 Proteins 0.000 description 1
- 101000617921 Homo sapiens VPS10 domain-containing receptor SorCS2 Proteins 0.000 description 1
- 101000854951 Homo sapiens Wings apart-like protein homolog Proteins 0.000 description 1
- 101000818829 Homo sapiens Zinc finger protein 429 Proteins 0.000 description 1
- 102100028084 Hyaluronan and proteoglycan link protein 1 Human genes 0.000 description 1
- 101710191341 Hyaluronan and proteoglycan link protein 1 Proteins 0.000 description 1
- CHSYCOLLKIBKNZ-UHFFFAOYSA-N I.I.I.I.I Chemical compound I.I.I.I.I CHSYCOLLKIBKNZ-UHFFFAOYSA-N 0.000 description 1
- 102100022514 Immunoglobulin superfamily member 1 Human genes 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
- 102100033474 Interleukin-36 alpha Human genes 0.000 description 1
- 102100033557 Kelch-like protein 29 Human genes 0.000 description 1
- 102100032431 Kinetochore protein Nuf2 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100027495 Leucine-rich repeat-containing protein 38 Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100031550 Microtubule-associated tumor suppressor 1 Human genes 0.000 description 1
- 102100038828 Mitotic spindle assembly checkpoint protein MAD1 Human genes 0.000 description 1
- 241000204801 Muraenidae Species 0.000 description 1
- 101100264174 Mus musculus Xiap gene Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 101710110239 NADH-quinone oxidoreductase subunit I Proteins 0.000 description 1
- 102100023305 Nesprin-2 Human genes 0.000 description 1
- 102100029051 Neuronal PAS domain-containing protein 3 Human genes 0.000 description 1
- 102100037371 Nidogen-2 Human genes 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102100026652 Olfactory receptor 9Q1 Human genes 0.000 description 1
- 102100021079 Ornithine decarboxylase Human genes 0.000 description 1
- 241000282322 Panthera Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 102100025008 Phosphatidate cytidylyltransferase, mitochondrial Human genes 0.000 description 1
- 102100033524 Potassium channel subfamily T member 2 Human genes 0.000 description 1
- 102100041031 Probable G-protein coupled receptor 158 Human genes 0.000 description 1
- 102100031575 Probable phospholipid-transporting ATPase IIB Human genes 0.000 description 1
- 102100038589 Protein Daple Human genes 0.000 description 1
- 102100020729 Protein Wnt-7a Human genes 0.000 description 1
- 102100034957 Protocadherin-9 Human genes 0.000 description 1
- 102100035255 Putative uncharacterized protein SLC66A1L Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100036276 RING finger protein 150 Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108091007332 RNF150 Proteins 0.000 description 1
- 101100516335 Rattus norvegicus Necab1 gene Proteins 0.000 description 1
- 102100039666 Receptor-type tyrosine-protein phosphatase delta Human genes 0.000 description 1
- 102100022814 Repulsive guidance molecule B Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000012978 SLC1A4 Human genes 0.000 description 1
- 101100166255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CEP3 gene Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 102100024224 Sideroflexin-5 Human genes 0.000 description 1
- 101000921780 Solanum tuberosum Cysteine synthase Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102100030311 Spermatogenesis-associated protein 16 Human genes 0.000 description 1
- 102100035756 Stabilizer of axonemal microtubules 1 Human genes 0.000 description 1
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 1
- 101150059016 TFIP11 gene Proteins 0.000 description 1
- 102100036980 Talin-2 Human genes 0.000 description 1
- 102100040872 Tetraspanin-5 Human genes 0.000 description 1
- 101710151637 Tetraspanin-5 Proteins 0.000 description 1
- 102100031744 Tetratricopeptide repeat protein 28 Human genes 0.000 description 1
- 102100037766 Thrombospondin type-1 domain-containing protein 7B Human genes 0.000 description 1
- 101150045848 Tmbim6 gene Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102100022234 Trimeric intracellular cation channel type B Human genes 0.000 description 1
- 102100036105 Tubulin polyglutamylase TTLL11 Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 235000010730 Ulex europaeus Nutrition 0.000 description 1
- 102100021938 VPS10 domain-containing receptor SorCS2 Human genes 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 102100020735 Wings apart-like protein homolog Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 102100021352 Zinc finger protein 429 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 101150024767 arnT gene Proteins 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 101150031028 arpin gene Proteins 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 108010044208 calpastatin Proteins 0.000 description 1
- ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 238000004370 retrospective diagnosis Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 101150039612 rpsK gene Proteins 0.000 description 1
- 102220271781 rs1555575857 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- RLQWHDODQVOVKU-UHFFFAOYSA-N tetrapotassium;silicate Chemical compound [K+].[K+].[K+].[K+].[O-][Si]([O-])([O-])[O-] RLQWHDODQVOVKU-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893807P | 2013-10-21 | 2013-10-21 | |
| US61/893,807 | 2013-10-21 | ||
| US201462048127P | 2014-09-09 | 2014-09-09 | |
| US62/048,127 | 2014-09-09 | ||
| US201462048641P | 2014-09-10 | 2014-09-10 | |
| US62/048,641 | 2014-09-10 | ||
| PCT/US2014/061647 WO2015061367A1 (en) | 2013-10-21 | 2014-10-21 | Genetic markers predictive of response to glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2926724A1 true CA2926724A1 (en) | 2015-04-30 |
Family
ID=52826364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2926724A Abandoned CA2926724A1 (en) | 2013-10-21 | 2014-10-21 | Genetic markers predictive of response to glatiramer acetate |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9702007B2 (enExample) |
| EP (1) | EP3060681A4 (enExample) |
| JP (1) | JP2016540729A (enExample) |
| KR (1) | KR20160098199A (enExample) |
| CN (1) | CN105658818A (enExample) |
| AU (1) | AU2014340247A1 (enExample) |
| CA (1) | CA2926724A1 (enExample) |
| EA (1) | EA201690759A1 (enExample) |
| IL (1) | IL244783A0 (enExample) |
| MX (1) | MX2016005003A (enExample) |
| TW (1) | TW201610166A (enExample) |
| UY (1) | UY35790A (enExample) |
| WO (1) | WO2015061367A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| BR112019017724A2 (pt) | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CU20210002A7 (es) | 2018-07-10 | 2021-08-06 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN111088368B (zh) * | 2019-12-30 | 2021-04-16 | 山西医科大学 | 一种血液mRNA检测试剂盒及检测方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| EP2090583B1 (en) | 1998-09-25 | 2011-07-13 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| JP2003522799A (ja) | 2000-02-18 | 2003-07-29 | イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス | コポリマー１の経口、経鼻および経肺投与製剤 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| PL363431A1 (en) | 2000-06-05 | 2004-11-15 | Teva Pharmaceuticals Industries, Ltd. | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| CA2469393C (en) | 2001-12-04 | 2010-05-25 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| EP1603530A1 (en) | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| HRP20140524T1 (hr) | 2003-05-14 | 2014-12-19 | Teva Pharmaceutical Industries Ltd. | Kombinacijska terapija glatiramer acetatom i mitoksantronom za lijeäśenje multiple skleroze |
| US20050064483A1 (en) | 2003-08-28 | 2005-03-24 | Baylor College Of Medicine | Gene expression profiling technology for treatment evaluation of multiple sclerosis |
| US20050170004A1 (en) | 2003-10-31 | 2005-08-04 | Vered Rosenberger | Nanoparticles for drug delivery |
| CA2558380A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US20060229233A1 (en) | 2004-06-25 | 2006-10-12 | Id Biomedical Corporation | Compositions and methods for treating neurological disorders |
| CA2579038A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| DK1797109T3 (en) | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| NZ554018A (en) | 2004-09-09 | 2009-06-26 | Teva Pharma | Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid |
| US20060172942A1 (en) | 2005-02-02 | 2006-08-03 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| HRP20130622T1 (en) | 2005-02-17 | 2013-08-31 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| EP1891233A4 (en) | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| CN101877963A (zh) | 2007-11-28 | 2010-11-03 | 泰华制药工业有限公司 | 延缓临床确诊的多发性硬化症发作的方法 |
| ES3058497T3 (en) * | 2008-09-17 | 2026-03-11 | Amryt Endo Inc | Pharmaceutical compositions comprising polypeptides and related methods of delivery |
| EP2406396A2 (en) * | 2009-03-12 | 2012-01-18 | Brainco Biopharma, S.L. | A genotyping tool for improving the prognostic and clinical management of ms patients |
| NZ577731A (en) * | 2009-06-16 | 2010-08-27 | Innate Therapeutics Ltd | Compositions and methods for treatment of multiple sclerosis |
| PL2275086T3 (pl) | 2009-07-15 | 2012-09-28 | Teva Pharma | Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| SG10201405806SA (en) | 2009-08-20 | 2014-11-27 | Yeda Res & Dev | Low Frequency Glatiramer Acetate Therapy |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| CN103636027B (zh) * | 2011-07-01 | 2015-10-21 | 日本瑞翁株式会社 | 二次电池用多孔膜、制造方法及用途 |
| AU2012323345A1 (en) * | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| KR20150111919A (ko) | 2012-12-21 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트의 경구 경점막 전달 |
| AU2013361053A1 (en) | 2012-12-21 | 2015-07-30 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate |
| EP2941274A4 (en) | 2013-01-04 | 2016-11-16 | Teva Pharma | CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE |
| TW201521757A (zh) | 2013-03-12 | 2015-06-16 | Teva Pharma | 先後通過利妥昔單抗（ｒｉｔｕｘｉｍａｂ）誘導治療及格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）治療 |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2014
- 2014-10-20 UY UY0001035790A patent/UY35790A/es not_active Application Discontinuation
- 2014-10-21 CN CN201480058055.6A patent/CN105658818A/zh active Pending
- 2014-10-21 AU AU2014340247A patent/AU2014340247A1/en not_active Abandoned
- 2014-10-21 MX MX2016005003A patent/MX2016005003A/es unknown
- 2014-10-21 WO PCT/US2014/061647 patent/WO2015061367A1/en not_active Ceased
- 2014-10-21 EA EA201690759A patent/EA201690759A1/ru unknown
- 2014-10-21 JP JP2016522037A patent/JP2016540729A/ja not_active Withdrawn
- 2014-10-21 EP EP14855499.1A patent/EP3060681A4/en not_active Withdrawn
- 2014-10-21 KR KR1020167013482A patent/KR20160098199A/ko not_active Withdrawn
- 2014-10-21 US US14/520,280 patent/US9702007B2/en active Active
- 2014-10-21 CA CA2926724A patent/CA2926724A1/en not_active Abandoned
- 2014-10-21 TW TW103136383A patent/TW201610166A/zh unknown
-
2016
- 2016-03-28 IL IL244783A patent/IL244783A0/en unknown
-
2017
- 2017-01-19 US US15/410,091 patent/US20180002753A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201610166A (zh) | 2016-03-16 |
| US9702007B2 (en) | 2017-07-11 |
| EP3060681A1 (en) | 2016-08-31 |
| CN105658818A (zh) | 2016-06-08 |
| AU2014340247A1 (en) | 2016-06-02 |
| KR20160098199A (ko) | 2016-08-18 |
| IL244783A0 (en) | 2016-04-21 |
| US20180002753A1 (en) | 2018-01-04 |
| EP3060681A4 (en) | 2017-06-07 |
| UY35790A (es) | 2015-05-29 |
| WO2015061367A1 (en) | 2015-04-30 |
| JP2016540729A (ja) | 2016-12-28 |
| US20150110733A1 (en) | 2015-04-23 |
| MX2016005003A (es) | 2016-08-03 |
| EA201690759A1 (ru) | 2017-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verstraeten et al. | Progress in unraveling the genetic etiology of Parkinson disease in a genomic era | |
| Mrazek et al. | SLC6A4 variation and citalopram response | |
| EP2639318B1 (en) | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | |
| US9499868B2 (en) | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate | |
| US9702007B2 (en) | Genetic markers predictive of response to glatiramer acetate | |
| WO2013160315A2 (en) | Genetic predictors of response to treatment with crhr1 antagonists | |
| Diaz-Molina et al. | Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation | |
| HUE028075T2 (en) | Rostafuroxin for the pharmacogenomic treatment of cardiovascular conditions | |
| Yoo et al. | Putative functional variants of XRCC1 identified by RegulomeDB were not associated with lung cancer risk in a Korean population | |
| Huang et al. | Spectrum of β-thalassemia mutations in Guizhou Province, PR China, including first observation of codon 121 (GAA> TAA) in Chinese population | |
| CA3035386A1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| Castaldo et al. | Detection of five rare cystic fibrosis mutations peculiar to Southern Italy: implications in screening for the disease and phenotype characterization for patients with homozygote mutations | |
| WO2014202541A1 (en) | Method for predicting a treatment response to a crhr1 antagonist and/or a v1b antagonist in a patient with depressive and/or anxiety symptoms | |
| Haerian et al. | Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy | |
| Porubsky et al. | Haplotype-resolved inversion landscape reveals hotspots of mutational recurrence associated with genomic disorders | |
| US9650678B2 (en) | Methods for identifying an increased risk of anthracycline-related cardiotoxicity | |
| Roberts et al. | A founder mutation in MYO7A underlies a significant proportion of Usher syndrome in indigenous South Africans: implications for the African diaspora | |
| US20160312284A1 (en) | Select single nucleotide polymorphisms predictive of response to glatiramer acetate | |
| US20050250118A1 (en) | EPHX2 Genetic markers associated with galantamine | |
| KR20230005816A (ko) | 신경전달물질 수송체 억제제의 효능을 평가하기 위한 조성물 및 방법 | |
| US20130236893A1 (en) | Method of detecting type ii diabetes | |
| US20050260613A1 (en) | LRPAP1 genetic markers associated with galantamine | |
| WO2004067763A2 (en) | Genetic diagnosis of alcoholism subtypes | |
| WO2012054653A2 (en) | Diagnostic kits, genetic markers, and methods for scd or sca therapy selection | |
| Weitzman | Genomic and Transcriptomic Variation of H1 and H2 Haplotypes at 17q21. 31 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20191022 |